衣晓丽;刘晓明;刘天峰;周剑锋;万扬;张家源;张丽;邹尧;陈玉梅;竺晓凡;

• 1:山东省青岛市市立医院肿瘤科
• 2:中国医学科学院血液学研究所血液病医院
• 3:金域医学检验所有限公司

摘要(Abstract)：

目的分析CCLG-ALL2008方案治疗初诊儿童急性淋巴细胞白血病(ALL)诱导治疗期感染并发症发生情况。方法搜集2008年至2011年339例初诊儿童急性淋巴细胞白血病(ALL)在诱导治疗期感染情况并进行分析,评价标危组(SR)、中危组(MR)、高危组(HR)间感染差异、常见感染部位、感染病原体分布。结果303例患儿完成诱导治疗,36例未进入统计范围,包括16例曾院外治疗,10例诊断后放弃治疗,7例在诱导治疗中期放弃治疗(其中3例患儿初诊时伴有肺炎),2例混合白血病,1例T细胞型且合并肾衰竭放弃治疗。SR 151例,男96例,女55例,性别比1.75:1,中位年龄4(1~9)岁;MR 81例,男46例,女35例,性别比1.31:1,中位年龄6岁(6个月~14岁);HR 71例,男47例,女24例,性别比1.96:1,中位年龄10(1~15)岁。195例患儿诱导期出现感染,总感染率为64.36%(195/303),三组感染率分别为64.9%,64.19%,63.38%,差异无显著性(P=0.996)。感染相关死亡率3.63%(11/303)。110例患儿感染部位明确(110/195,56.41%),发生频率依次为呼吸道、血液、口腔、消化道、皮肤和软组织,发生率分别为82.72%、30%、11.82%、6.32%、2.72%。疑似真菌感染37.43%(73/195),病原菌明确的感染为42例次(42/110,38.18%),G菌感染29例次(29/41,70.73%),G~+菌感染12例次(12/41,29.27%),真菌感染1例。常见病原菌依次为肺炎克雷伯菌、大肠埃希菌、铜绿假单胞菌。结论CCLG-ALL 2008诱导化疗在各组间的感染率无显著差异;感染部位以呼吸道为主;病原菌种类以G~-为主;感染多发生在诱导治疗中期;低龄患儿、粒缺及粒缺持续时间是感染高危因素,感染无性别差异。

关键词(KeyWords)： 急性淋巴细胞白血病,儿童;诱导化疗;感染

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 衣晓丽;刘晓明;刘天峰;周剑锋;万扬;张家源;张丽;邹尧;陈玉梅;竺晓凡;

Email:

DOI:

参考文献(References)：

• 1.Pui CH,Pei D,Sandlund JT,et al.Long-term results of St Jude Total Therapy Studies 11,12,13A,13B,and 14 for childhood acute lymphoblastic leukemia.Leukemia,2010,24:371-382.
• 2.Pui CH,Robison LL,Look AT.Acute lymphoblastic leukaemia.Lancet,2008,371:1030-1043.
• 3.顾龙君,李娟,薛惠良,等.ALL-XH-99方案治疗儿童急性淋巴细胞白血病158例疗效分析.中华血液学杂志,2004,25:1-4.
• 4.汤静燕,薛惠良,顾龙君,等.儿童急性淋巴细胞性白血病治疗依从失败及治疗失败分析.中华儿科杂志,2005,43:490-493.
• 5.Pui CH,Boyett JM,Rivera GK,et al.Long-term results of Total Therapy studies 11,12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital.Leukemia,2000,14:2286-2294.
• 6.盛琦,陈同辛,张勤,等.治疗相关性白血病患儿死亡原因分析.临床儿科杂志,2005,23:542-544.
• 7.林素霞,刘永武,严俊,等.急性白血病院内感染临床分析.白血病.淋巴瘤,2005,14:236-237.
• 8.张之南,沈悌.血液病诊断及疗效标准[M].3版.2007;19-23.
• 9.张乐萍、程翼飞,刘桂兰,等.急性B淋巴细胞白血病患儿微小残留病流式细胞术检测的临床意义.中华儿科杂志,2005,43:481-485.
• 10.Hughes WT,Armstrong D,Bodey GP,et al.2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.Clin Infect Dis,2002,34:730-751.
• 11.于洁,陈波,宪莹,等.CCLG-ALL08方案治疗儿童急性淋巴细胞白血病毒副作用的临床研究.中国当代儿科杂志,2013,15:737-742.
• 12.Eyrich M,Wiegering V,Lim A,et al.Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemiaa prospective study of 20 paediatric patients.Br J Haematol,2009,147;360-370.
• 13.OConnor D,Bate J,Wade R,et al.Infection-related mortality in children with acute lymphoblastic leukemia:an analysis of infectious deaths on UKALL2003.Blood,2014,124:1056-1061.
• 14.Inaba H,Pei D,Wolf J,et al.Infection-related complications during treatment for childhood acute lymphoblastic,leukemia.Annals of Oncology,2017,28:386-392.
• 15.Li MJ,Chang HH,Yang YL,et al.Infectious complications in children with acute lymphoblastic leukemia treated with the Taiwan Pediatric Oncology Group protocol:A 16-year tertiary singleinstitution experience.Pediatr Blood Cancer,2017,64:1-9.
• 16.Dare JM,Moppett JP,Shield JP,et al.The Impact of Hyperglycemia on Risk of Infection and Early Death During Induction Therapy for Acute Lymphoblastic Leukemia(ALL).Pediatr Blood Cancer,2013,60:E157-E159.
• 17.Kocak U,Gursel T,Kaya Z,et al.ALL-BFM 95 Treatment in Turkish Children with Acute Lymphoblastic Leukemia—Experience of a Single Center.Pediatr Hematol Oncol,2012,29:130-140.
• 18.Asim M,Zaidi A,Ghafoor T,et al.Death analysis of childhood acute lymphoblastic leukaemia;experience at Shaukat Khanum Memorial Cancer Hospital and Research Centre,Pakistan.J Pak Med Assoc,2011,61:666-670.
• 19.Rackoff WR,Ge J,Sather HN,et al.Central venous catheter use and the risk of infection in children with acute lymphoblastic leukemia:a report from the Children's Cancer Group.J Pediatr Hematol Oncol,1999,21:260-267.
• 20.Katsimpardi K,Papadakis V,Parcharidou A,et al.Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment.Support Care Cancer,2006,14:277-284.
• 21.陈再生,郑灵,陈以乔,等.儿童急性淋巴细胞白血病诱导缓解期感染的病原菌及耐药情况分析.中国当代儿科杂志,2017,2:176-181.
• 22.Graubner UB,Porzig S,Jorch N,et al.Impact of Reduction of Therapy on Infectious Complications in Childhood Acute Lymphoblastic Leukemia.Pediatr Blood Cancer,2008,50:259-263.
• 23.Vehreschild JJ,B(o|¨)hme A,Buchheidt D,et al.A double-blind trial on prophylactic voriconazole(VRC)or placebo during induction chemotherapy for acute myelogenous leukaemia(AML).J Infect,2007,55:445-449.
• 24.Bakhshi S,Padmanjali KS,Arya LS.Infections in childhood acute lymphoblastic leukemia:an analysis of 222 febrile neutropenicepisodes.Pediatric hematology and oncology."Pediatr Hematol Oncol,2008,25:385-392.
• 25.Gardner A,Mattiuzzi G,Faderl S,et al.Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.J Clin Oncol,2008,26:5684-5688.
• 26.Hakim H,Flynn PM,Knapp KM,et al.Etiology and Clinical Course of Febrile Neutropenia in Children with Cancer.J Pediatr Hematol Oncol,2009,31:623-629.
• 27.Yilmaz S,(O|¨)ren H,Demircioglu F,et al.Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFMprotocols.Pediatr Hematol Oncol,2008,25:19-204.
• 28.Meir HM,Balawi IA,Meer HM,et al.Fever and granulocytopenia in children with Acute Lymphoblastic Leukemia under induction therapy.Saudi Med J,2001,22:423-427.
• 29.GuptaA,Singh M,Singh H,et al.Infections in acute myeloid leukemia:an analysis of 382 febrile episodes.Med Oncol,2010,27:1037-1045.
• 30.Auletta JJ,O'Riordan MA,Nieder ML,et al.Infections in children with cancer:a continued need for the comprehensive physical examination.J Pediatr Hematol Oncol,1999,21:501-508.
• 31.Greenberg D,Moser A,Yagupsky P,et al.Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients:comparison between two consecutive time periods with use of different antibiotic treatment protocols.Int J Antimicrob Agents,2005,25:469-473.
• 32.Orudjev E,Lange BJ,et al.Evolving concepts of management of febrile neutropenia in children with cancer.Med Pediatr Oncol,2002,39:77-85.
• 33.Li SD,Chen YB,Li ZG,et al.Infections During Induction Therapy of Protocol CCLG-2008 in Childhood Acute Lymphoblastic Leukemia:A Single-center Experience with 256 Cases in China.Chinese Medical Journal,2015,128:472-476.
• 34.Clark OA,Lyman GH,Castro AA,et al.Colony-stimulating factors for chemotherapy induced febrile neutropenia:a meta-analysis of randomized controlled trials.J Clin Oncol,2005,23:4198-4214.
• 35.Sasse EC,Sasse AD,Brandalise S,et al.Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acutelymphoblastic leukaemia.Cochrane Database Syst Rev,2005,Jul 20;(3):CD004139.
• 36.Creutzig U,Zimmermann M,Lehrnbecher T,et al.Less toxicity by optimizing chemotherapy,but not by addition of granulocyte colonystimulating factor in children and adolescents with acute myeloid leukemia:results of AML-BFM 98.J Clin Oncol,2006,24:4499-4506.
• 37.Slavin MA,Thursky KA,Worth LJ,et al.Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology,2014.Internal Medicine Journal,2014,44:1267-1276.
• 38.Hafsteinsd6ttir S,Jónasson K,Jónmundsson,et al.Suspected infections in children treated for ALL.Acta Paediatrica,2009,98:1149-1155.
• 39.Prucker C,Attarbaschi A,Peters C,et al.Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia:a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group.Leukemia,2009,23:1264-269.